Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: '584 is Officially Recertified

The BOD was remunerated when the stock price went to $2.25 a share. They could have really been remunerated further if the stock price would NOT have tanked; hence, the stock options provided good compensation for a short time. Then the BOD decided to issue dividends to stockholders along with outstanding warrant holders. If the BOD had done a good job when revenue started coming in, then the BOD and all stakeholders would have been able to participate. Instead, the BOD provided a small window to grab gains; otherwise, you were sent on a declining stock odyssey for the last three years.

Once again, reasonable compensation with stock options should be offered to the BOD. NOT outrageous payouts without any accountability.

Share
New Message
Please login to post a reply